Agile Therapeutics, Inc.
AGRX
Price:
$1.51
Market Cap:
$10.43M
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend t...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2014-05-23
Stock Exchange
NASDAQ
Ticker
AGRX
PE Ratio
[-0.89]
ROE
[104.04%]
Current Ratio
[0.55]
Dividend Yield
[0%]
Enterprise Value
[7.87M]
Dividend History
The ROE as of December 2024 (TTM) for Agile Therapeutics, Inc. (AGRX) is 104.04%
According to Agile Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 104.04%. This represents a change of 450.66% compared to the average of 18.89% of the last 4 quarters.
Agile Therapeutics, Inc. (AGRX) Historical ROE (quarterly & annually)
How has AGRX ROE performed in the past?
The mean historical ROE of Agile Therapeutics, Inc. over the last ten years is -82.09%. The current 104.04% ROE has changed -226.74% with respect to the historical average. Over the past ten years (40 quarters), AGRX's ROE was at its highest in in the December 2022 quarter at 239.48%. The ROE was at its lowest in in the March 2022 quarter at -429.06%.
Average
-82.09%
Median
-72.94%
Minimum
-826.07%
Maximum
458.29%
Agile Therapeutics, Inc. (AGRX) ROE by Quarter and Year
Discovering the peaks and valleys of Agile Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 645.13%
Maximum Annual ROE = 458.29%
Minimum Annual Increase = -322.75%
Minimum Annual ROE = -826.07%
| Year | ROE | Change |
|---|---|---|
| 2023 | 88.64% | -80.66% |
| 2022 | 458.29% | -155.48% |
| 2021 | -826.07% | 645.13% |
| 2020 | -110.86% | 174.98% |
| 2019 | -40.32% | -58.88% |
| 2018 | -98.04% | 25.82% |
| 2017 | -77.92% | 14.65% |
| 2016 | -67.96% | -33.36% |
| 2015 | -101.99% | 128.42% |
| 2014 | -44.65% | -322.75% |
Agile Therapeutics, Inc. (AGRX) Average ROE
How has AGRX ROE performed in the past?
The current ROE of Agile Therapeutics, Inc. (AGRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-93.05%
5-year avg
-86.06%
10-year avg
-82.09%
Agile Therapeutics, Inc. (AGRX) ROE vs. Peers
How is AGRX’s ROE compared to its peers?
Agile Therapeutics, Inc.’s ROE is greater than Assertio Holdings, Inc. (-51.19%), less than Amneal Pharmaceuticals, Inc. (378.68%), greater than AcelRx Pharmaceuticals, Inc. (-118.55%), less than Lifecore Biomedical, Inc. (17.23%), less than Guardion Health Sciences, Inc. (77.24%), greater than Alpha Teknova, Inc. (-37.32%), less than Cyclo Therapeutics, Inc. (749.85%), greater than Petros Pharmaceuticals, Inc. (-122.55%), greater than Shuttle Pharmaceuticals Holdings, Inc. (-582.98%), greater than Mallinckrodt plc (-74.45%), less than Athenex, Inc. (21.51%), greater than Evoke Pharma, Inc. (-308.51%), greater than Cumberland Pharmaceuticals Inc. (-40.17%), greater than PainReform Ltd. (-450.64%), less than Aquestive Therapeutics, Inc. (62.93%),
| Company | ROE | Market cap |
|---|---|---|
| -51.19% | $83.65M | |
| 378.68% | $3.63B | |
| -118.55% | $14.58M | |
| 17.23% | $279.89M | |
| 77.24% | $4.35M | |
| -37.32% | $458.45M | |
| 749.85% | $17.12M | |
| -122.55% | $2.89M | |
| -582.98% | $2.83M | |
| -74.45% | $4.52M | |
| 21.51% | $2.33M | |
| -308.51% | $7.28M | |
| -40.17% | $35.25M | |
| -450.64% | $2.62M | |
| 62.93% | $320.95M |
Build a custom stock screener for Agile Therapeutics, Inc. (AGRX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Agile Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Agile Therapeutics, Inc. (AGRX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Agile Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Agile Therapeutics, Inc.'s ROE?
How is the ROE calculated for Agile Therapeutics, Inc. (AGRX)?
What is the highest ROE for Agile Therapeutics, Inc. (AGRX)?
What is the 3-year average ROE for Agile Therapeutics, Inc. (AGRX)?
What is the 5-year average ROE for Agile Therapeutics, Inc. (AGRX)?
How does the current ROE for Agile Therapeutics, Inc. (AGRX) compare to its historical average?